Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Clin Oncol. Nov 24, 2022; 13(11): 918-928
Published online Nov 24, 2022. doi: 10.5306/wjco.v13.i11.918
Table 2 Patient demographics
VariableTotalMVI
P value
MVI group = 15
Non-MVI group = 35
Age (yr), mean (SD)67.0 (7.0)68.3 (8.8)66.4 (6.1)0.491
Gender0.348
Male, n (%)43 (86)12 (80)31 (89)
Female, n (%)7 (14)3 (20)4 (11)
Aetiology0.377
Alcohol, n (%)3 (6)0 (0)3 (8)
Hepatitis B, n (%)28 (56)7 (46)21 (60)
Hepatitis C, n (%)3 (6)1 (7)2 (6)
Hepatitis B and C, n (%)1 (2)1 (7)0 (0)
NAon-alcoholic steatohepatitis, n (%)1 (2)1 (7)0 (0)
Cryptogenic cirrhosis, n (%)5 (10)2 (13)3 (8)
De novo, n (%)9 (18)3 (20)6 (17)
HbSAg0.676
Positive, n (%)27 (54)7 (46)20 (57)
Negative, n (%)22 (44)8 (54)14 (40)
Unknown, n (%)1 (2)0 (0)1 (3)
Pre-operative serology
Alpha-fetoprotein (UG/L), mean (SD)248.0 (893.2)777.7 (1571.4)32.9 (105.6)0.065
Albumin (g/L), mean (SD)36.3 (5.8)35.4 (5.6)36.7 (5.9)0.374
Bilirubin (µmol/L), mean (SD)19.5 (12.1)18.6 (7.1)19.9 (13.8)0.797